The FDA expanded its approval for CAR-T therapy in treating cancer patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Read the full post on Becker's Hospital Review - Healthcare News
FDA expands CAR-T therapy approval
